Modulation of TRPV1 on Odontoblast-like Cells Using Capsazepine-Loaded Nanogels

Lilia Jadith Bernal-Cepeda1, Ronald Andrés Jiménez2, Myriam L Velandia-Romero3

  • 1IBAPO Group, School of Dentistry, Universidad Nacional de Colombia, Bogota 111321, Colombia.

Pharmaceutics
|March 28, 2024
PubMed

Insights

This study developed a nanogel delivery system for Capsazepine (CZP) to manage dental pain by modulating TRPV1. The system effectively delivered CZP, reducing calcium fluxes in dental cells and showing promise for local pain management.

Area of Science:

  • Biomaterials Science
  • Pain Management
  • Cell Biology

Background:

  • Transient Receptor Potential Vanilloid 1 (TRPV1) modulation is a key strategy for managing dental pain.
  • Developing effective delivery systems is crucial for localized therapeutic action and minimizing side effects.

Purpose of the Study:

  • To assess TRPV1 modulation in a human odontoblast-like cell model using Capsazepine (CZP) delivered via a nanogel system.
  • To characterize the nanogel properties and evaluate its efficacy in modulating TRPV1 activity.

Main Methods:

  • Gelatin nanogels loaded with CZP were synthesized using emulsification-gelation.
  • Nanogel characterization included HPLC for loading efficiency and light microscopy for size analysis.
  • TRPV1 expression and calcium fluxes were assessed in odontoblast-like cells post-treatment.

Main Results:

  • High CZP loading efficiency (67.5%) and optimal nanogel size (300-950 nm) were achieved.
  • CZP-loaded nanogels demonstrated low cytotoxicity and no adverse chemical interactions.
  • Cells treated with CZP-loaded nanogels showed increased TRPV1 expression and reduced calcium influx post-stimulation.

Conclusions:

  • The developed nanogel system is an economical and effective method for delivering CZP to modulate TRPV1.
  • This system holds significant promise for localized dental pain management with reduced systemic adverse effects.